List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. North America Minimal Residual Disease Testing Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of North America Minimal Residual Disease Testing Market 24
Figure 7. World Number of Deaths from Cancers in 201 27
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 10. Primary Restraints and Impact Factors of North America Minimal Residual Disease Testing Market 30
Figure 11. Investment Opportunity Analysis 34
Figure 12. Porter’s Fiver Forces Analysis of North America Minimal Residual Disease Testing Market 37
Figure 13. Breakdown of North America Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 42
Figure 14. North America Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 42
Figure 15. North America Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 43
Figure 16. North America Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 44
Figure 17. Breakdown of North America Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 46
Figure 18. North America Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 46
Figure 19. North America Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 47
Figure 20. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 49
Figure 21. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 50
Figure 22. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 51
Figure 23. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 52
Figure 24. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 53
Figure 25. North America Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 54
Figure 26. North America Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 55
Figure 27. North America Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 56
Figure 28. North America Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 57
Figure 29. North America Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 58
Figure 30. North America Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 59
Figure 31. North America Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 60
Figure 32. North America Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 61
Figure 33. North America Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 62
Figure 34. Breakdown of North America Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 64
Figure 35. North America Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 64
Figure 36. North America Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 65
Figure 37. North America Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 66
Figure 38. North America Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 67
Figure 39. North America Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 68
Figure 40. Breakdown of North America Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 70
Figure 41. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 70
Figure 42. North America Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 71
Figure 43. North America Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 72
Figure 44. North America Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 73
Figure 45. North America Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 74
Figure 46. Breakdown of North America Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 76
Figure 47. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 77
Figure 48. U.S. Minimal Residual Disease Testing Market, 2021-2031, $ mn 79
Figure 49. Canada Minimal Residual Disease Testing Market, 2021-2031, $ mn 81
Figure 50. Minimal Residual Disease Testing Market in Mexico, 2021-2031, $ mn 83
Figure 51. Growth Stage of North America Minimal Residual Disease Testing Industry over the Forecast Period 85
North America minimal residual disease (MRD) testing market is projected to grow by 11.1% annually in the forecast period and reach $ 1,056.1 million by 2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure. Highlighted with 27 tables and 51 figures, this 108-page report “North America Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country. Based on Offering, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Services • Test Kits & Consumables Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Non-Hodgkin's Lymphoma (NHL) o DLBCL o Marginal Zone Lymphoma o Follicular Lymphoma o Peripheral T-cell Lymphoma o Mantle Cell Lymphoma o Other NHLs • Multiple Myeloma (MM) • Acute Lymphoblastic Leukemia (ALL) • Chronic Lymphoblastic Leukemia (CLL) • Acute Myeloid Leukemia (AML) • Chronic Myeloid Leukemia (CML) • Hodgkin's Lymphoma (HL) • Solid Tumor • Other Applications By Technology, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Flow Cytometry • Polymerase Chain Reaction (PCR) • Next-Generation Sequencing (NGS) • Other Technologies By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals and Clinics • Research Institutions • Diagnostic Laboratories • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Adaptive Biotechnologies Corporation ArcherDX, Inc. (Invitae Corporation) Arup Laboratories Asuragen Inc. Bio-Rad Laboratories, Inc. Cergentis B.V. Guardant Health ICON plc Inivata Ltd. Invivoscribe, Inc. Laboratory Corporation of America Holdings Mission Bio, Inc. Natera, Inc. NeoGenomics Laboratories, Inc. Opko Health, Inc. Quest Diagnostics Incorporated Sysmex Corporation (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More